The Construction and Application of Therapeutic System of Intelligent Decision-Oriented Hemodynamic Organized Therapy for Shock Patients

Sponsor
Peking Union Medical College Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05886192
Collaborator
(none)
60
1
2
29
2.1

Study Details

Study Description

Brief Summary

Patients with septic shock with norepinephrine >0.25ug/kg/min were enrolled. Informed consent was obtained for inclusion in the study and random assignment into the combination or norepinephrine group.

Contact the research assistant to obtain patient number information and print out the appropriate labels.Notify the ward dispensing nurse to open the experimental drug cassette (placed in the refrigerator 4℃ drug cabinet).

Extract the corresponding experimental medication according to the patient label number, dispense it and send it to the ward, label it and hand it over to the bedside nurse to start using it. The time point at which the medication was connected to the patient and activated was recorded as the zero point for the start of the study.

The data were monitored according to the time points specified in the study: baseline,0h , 6h, D1, D2, and post-drug withdrawal.

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
The Construction and Application of Therapeutic System of Intelligent Decision-Oriented Hemodynamic Organized Therapy for Shock Patients
Actual Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
Jan 1, 2025
Anticipated Study Completion Date :
Sep 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: norepinephrine+vasopressin

norepinephrine+vasopressin

Drug: norepinephrine+vasopressin
Norepinephrine combined with vasopressin to maintain blood pressure

Placebo Comparator: Norepinephrine

norepinephrine

Drug: Norepinephrine
norepinephrine

Outcome Measures

Primary Outcome Measures

  1. 28days-Mortality in ICU [28 days]

    28 day mortality rate

  2. ICU duration [an average of 1 year]

    Residence time in ICU

Secondary Outcome Measures

  1. RVDEA/LVDEA [baseline,0hour, 6hour, Day1, Day2, and post-drug withdrawal(within 1week)]

    bedside cardiac ultrasound parameters,Qualitative indicators: RVDEA/LVDEA

  2. right ventricular thickness [baseline,0hour, 6hour, Day1, Day2, and post-drug withdrawal(within 1week)]

    bedside cardiac ultrasound parameters qualitative indicators: right ventricular thickness,

  3. Tricuspid Annular Plane Systolic Excursion [baseline,0hour, 6hour, Day1, Day2, and post-drug withdrawal(within 1week)]

    Right ventricular systolic function indicators: Tricuspid,Annular,Plane,Systolic,Excursion (TAPSE) Right ventricular pressure indicators: TV max, peak pulmonary artery regurgitation Other cardiac parameters: E/A, E/E'.

  4. resistance index of superior mesenteric artery [baseline,0hour, 6hour, Day1, Day2, and post-drug withdrawal(within 1week)]

    Blood flow parameters of superior mesenteric artery: resistance index 2) VexUS: Liver vein, portal vein, and renal vein. 3) Arterial pressure monitoring waveform. 4) Intestinal ultrasound score

  5. venous excess ultrasound grading system(VexUS) [baseline,0hour, 6hour, Day1, Day2, and post-drug withdrawal(within 1week)]

    Liver vein, portal vein, and renal vein.

  6. Intestinal ultrasound score [baseline,0hour, 6hour, Day1, Day2, and post-drug withdrawal(within 1week)]

    Intestinal ultrasound score :Including the diameter of the small intestine, the thickness of the small intestine wall, and the frequency of small intestine peristalsis

  7. pulsatility index of the middle cerebral artery [baseline,0hour, 6hour, Day1, Day2, and post-drug withdrawal(within 1week)]

    Cranial ultrasound measurement indexes Cranial ultrasound measurement indexes: pulsatility index of the middle cerebral artery

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Septic shock patients with norepinephrine>0.25ug/kg/min

Exclusion Criteria:
  1. Under 18 years of age

  2. Acute coronary syndrome requiring treatment

  3. have been treated with VA-ECMO

  4. VV-ECMO treatment has been administered for less than 12 hours

  5. Patient is on posterior pituitary hormone

  6. Patients with liver failure with a Model for End-Stage Liver Disease (MELD) score ≥ 30

  7. Patients requiring more than 500 mg of hydrocortisone or equivalent glucocorticoid daily as a fixed dose

  8. absolute neutrophil counts below 1,000/mm3

  9. Patients with active bleeding who are expected to require (within 48 hours of study entry) transfusion of more than 4 units of red blood cell concentrate patients with active bleeding that is expected to require (within 48 hours of study entry) transfusion of more than 4 units of red blood cell concentrate

  10. malignancy or other irreversible disease or condition with an estimated 6-month mortality rate of ≥50%

  11. Confirmed or suspected acute mesenteric ischemia. If the investigator believes that the patient's condition is highly suspicious but not confirmed by conventional criteria The investigator may exclude a patient if, in the opinion of the investigator, the patient's condition is highly suspicious but not confirmed by conventional criteria, or if the treating physician has initiated empiric therapy.

  12. Likely death expected within 12 hours

  13. Family or physician plans to implement a palliative care plan for the patient

Contacts and Locations

Locations

Site City State Country Postal Code
1 Peking Union Medical College Hospital Beijing Beijing China 100730

Sponsors and Collaborators

  • Peking Union Medical College Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peking Union Medical College Hospital
ClinicalTrials.gov Identifier:
NCT05886192
Other Study ID Numbers:
  • 2022-PUMCH-B-115
First Posted:
Jun 2, 2023
Last Update Posted:
Jun 2, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Peking Union Medical College Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 2, 2023